Stage III NSCLC, a heterogeneous group of disease, constitutes around 30% comprising a broad disease spectrum and diversified treatment options. Discussion in multidisciplinary tumor board (MDT) when deciding personalized treatment options are recommended but are not routinely available for all stage III NSCLC cases in China. This survey study aims to identify heterogeneity in the treatment patterns among Chinese specialists for stage III NSCLC in the real-world setting. The study is a self-administered, cross-sectional, descriptive, internet-based or paper-based survey. The questionnaire consists of 5 sessions: Demographics, Staging Practice, Resectability, Treatment Paradigm, Case Scenarios and a total of 37 multiple-choice questions. The internet-based survey was sent to radiation oncologists, medical oncologists, pulmonologists and thoracic surgeons involved in the treatment of lung cancer patients in May 2020 in China, Hong Kong and Macau. Descriptive summary and bivariate analysis are used to analyse the data. Chi-square test were used to measure the association of response from each question with demographic factors. Statistical significance is defined at 0.05 level for 2-tailed test. This preliminary analysis included 59 specialists (5.1% medical oncologists, 28.8% radiation oncologists, 66.1% thoracic surgeons) in China, Macau and Hong Kong, 71.2% of them with > 20 years’ experience, 25.4% treated >10 cases stage III NSCLC patients each month (35.9% surgeons, 5% oncologist p=0.013), and 51.8 % discussed >50% cases in MDT meetings, of which 49.2% digital media platform is used. PET-CT staging was considered routine in 45.8% (28.2% surgeons, 80% oncologists) and MRI brain 84.7% (33.1% surgeons, 100% oncologists). All specialists generally agreed interlobular N1, hilar N1, single station N2 and lower mediastinal N2 as resectable disease, and 23.7% considered N2 >2cm as bulky (33.3% surgeon, 5% oncologists, p<0.001). The preferred chemotherapy for definitive chemoradiation for nonsqumous histology was cisplatin or carboplatin with pemetrexed (66.1%). 45.8% will consider adjuvant immunotherapy if no disease progression after definitive chemoradiotherapy. Consensus in treatment options and staging practice existed among specialists in South China, but with a certain extent of heterogeneity in the use of MRI brain and PET-CT scan, and criteria of resectability between oncologists and surgeons.